Mancini v. Boehringer Ingelheim Pharm., Inc. (In Re Mirapex Prods. Liab. Litig.)

912 F.3d 1129
CourtCourt of Appeals for the Eighth Circuit
DecidedJanuary 10, 2019
Docket17-2204
StatusPublished
Cited by15 cases

This text of 912 F.3d 1129 (Mancini v. Boehringer Ingelheim Pharm., Inc. (In Re Mirapex Prods. Liab. Litig.)) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eighth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Mancini v. Boehringer Ingelheim Pharm., Inc. (In Re Mirapex Prods. Liab. Litig.), 912 F.3d 1129 (8th Cir. 2019).

Opinion

LOKEN, Circuit Judge.

Mirapex is a dopamine agonist that is FDA-approved for treating adults with Parkinson's disease and movement disorders. On December 30, 2010, Marc Mancini filed this action against the defendant pharmaceutical companies, alleging they are liable for substantial gambling and other financial losses that resulted from obsessive compulsive behavior, a side effect of taking Mirapex. The action was filed in the District of Minnesota as part of the multi-district Mirapex Products Liability Litigation. Mancini appeals the district court's 1 grant of summary judgment dismissing all claims as barred by the applicable California statute of limitations. He argues the district court erred in not tolling the statute of limitations because he was "insane" and in rejecting his "continuing violations" theory, issues we review de novo , and abused its discretion in denying his motion to stay defendants' motion for summary judgment pending discovery. We affirm.

I. Background.

Mancini is a resident of California and a successful educator and travel industry speaker and consultant. In June 2004, doctors noted symptoms consistent with mild idiopathic Parkinson's disease. In January 2006, Dr. Mark Lew, Mancini's treating neurologist, prescribed Mirapex to treat worsening symptoms.

On January 3, 2008, Mancini reported to Dr. Lew that he experienced increased gambling and other compulsive behaviors after taking Mirapex. Dr. Lew's notes stated that Mancini reported "gambling and winning but not excessively." Dr. Lew informed Mancini of a possible association between Mirapex and compulsive behaviors such as gambling. On April 23, 2008, Mancini again reported gambling and other compulsive behaviors. Dr. Lew's notes from this visit stated that Mancini "has increasing stress at work" and "has become a bit more compulsive." "He tells me that this is controlled, and he does not have any significant problems," Dr. Lew wrote, "but with the stress, he has noted the compulsions to be a bit more intense. On occasion he ... described it as 'driving a car without brakes.' " Dr. Lew told Mancini he had "substantial and significant concerns" about Mancini's gambling and impulsive behavior. "We talked about the potential of simply cutting back on his Mirapex.... Currently he is quite resistant to this. He will return to see me in 3 months' time."

Mancini continued to take Mirapex until mid-July 2010, when his family learned of substantial debts resulting from gambling. Three days after stopping Mirapex, Mancini saw Dr. Lew, who noted worsening tremors but advised that Mancini "needs to stay off his Mirapex" and turn to other "therapeutic options." Dr. Lew's notes stated that "every visit I have had since [Mancini] has been on Mirapex for better than 5 years, we discuss[ed] the potential for compulsive behaviors, and he flat out denied any significant problem."

II. Discussion.

In reviewing whether Mancini's claims are time-barred, important issues are not disputed. The parties agree that California law governs the statute of limitations issue, and that California's two year statute of limitations for personal injury claims resulting from the ingestion of pharmaceutical drugs applies. See Cal. Code Civ. P. §§ 335.1, 340.8(a). The district court found, and Mancini does not dispute on appeal, that his claims initially accrued no later than April 23, 2008, because he suspected or should have suspected that he had been wronged by defendants as a result of his visits to Dr. Lew in January and April 2008. Thus, the claims filed in December 2010 appear to be time-barred. But Mancini argues the district court erred in granting summary judgment because the statute of limitations was tolled until July 2010, and because continuing violations are not time-barrred.

A. The Tolling Issue. As relevant here, section 352(a) of the California Code of Civil Procedure provides that, "[i]f a person entitled to bring an action ... is, at the time the cause of action accrued ... insane, the time of the disability is not part of the time limited for the commencement of the action." 2 Consistent with the statute's plain language, it applies even if the plaintiff's insanity is caused by the wrongful act of the defendant. See Feeley v. S. Pac. Transp. Co. , 234 Cal.App.3d 949 , 285 Cal.Rptr. 666 , 667 (1991). Thus, if Mancini was "insane" within the meaning of § 352(a) when his claim accrued in early 2008, the two-year statute of limitations would be tolled, presumably until he stopped taking Mirapex in July 2010. Mancini argues the district court erred in granting defendants summary judgment on this issue.

The statute, first enacted in 1872, does not define the word "insane." In an early case, the Supreme Court of California affirmed a jury verdict that the plaintiff was insane when the cause of action accrued:

It is true that the complaint and findings ... do not use the words "unsound" or "insane," but the finding that he was incapable of caring for his property or transacting business or understanding the nature or effects of his acts was equivalent to a finding in express terms that the deceased was insane within the meaning of the statute of limitations.

Pearl v. Pearl , 177 Cal. 303 , 177 P. 845 , 846 (1918). Many years later, in the leading case of Hsu v. Mt. Zion Hospital , 259 Cal.App.2d 562 , 66 Cal.Rptr. 659 , 664-67 (1968), the California Court of Appeal affirmed a jury verdict that plaintiff's claims were time-barred because she was not "insane" when the claims accrued, even though she was committed to a state hospital for the mentally disturbed shortly after the incident. The jury was instructed that, "to find that plaintiff was insane, you must find that she was incapable of caring for her property, or transacting business or understanding the nature or effects of her acts." Id. at 666 . The Court of Appeal ruled that this instruction "is taken directly from Pearl v. Pearl... and is a definition of insanity recognized by [other Court of Appeal] decisions." Id. The Court further explained:

The cases cited above, such as Pearl ...

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Harris v. Dignity Health CA2/6
California Court of Appeal, 2024
Pullen v. Jacuzzi CA4/1
California Court of Appeal, 2023
Wills v. Stiles
W.D. Missouri, 2023
Debonne v. Debonne CA4/2
California Court of Appeal, 2022
Webb v. Streeter
D. Nebraska, 2022
Webb v. Johnson
D. Nebraska, 2022
Cairns v. Kozel
D. Nebraska, 2021
ISD No. 283 v. E.M.D.H., a minor
960 F.3d 1073 (Eighth Circuit, 2020)
Irving v. Wells
E.D. Missouri, 2019
Marc L. Mancini v. Commissioner
2019 T.C. Memo. 16 (U.S. Tax Court, 2019)

Cite This Page — Counsel Stack

Bluebook (online)
912 F.3d 1129, Counsel Stack Legal Research, https://law.counselstack.com/opinion/mancini-v-boehringer-ingelheim-pharm-inc-in-re-mirapex-prods-liab-ca8-2019.